AQST 241220 7.50P (AQST241220P7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

AQST241220P7500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Aquestive Therapeutics: Strong Buy Rating Driven by Robust Revenue Performance and Strategic Positioning in Allergy Treatment
TipRanksNov 7 02:06 ET · Ratings
Aquestive Therapeutics Advances Drug Candidates Amid Challenges
TipRanksNov 6 16:40 ET
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10
Moomoo NewsNov 6 09:33 ET · Ratings
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsNov 6 06:31 ET · Ratings
Promising Future and Strategic Advancements: Buy Recommendation for Aquestive Therapeutics
TipRanksNov 6 06:25 ET

Comments

FU K D by moo

Nov 13 03:14

I bought in under $2.00, but I'm dumb and "high risk", so I have to close my account and can't wait till AQST pops up to $8-10. Screw me...!

Why does this company cut ties with someone who is doing great in the market and say they're a high risk?
Doesn't make sense to me?

Jaguar8

Oct 25 00:48

Good PR re Epi Sublingual med. Good biotech. Huge float

$Aquestive Therapeutics (AQST.US)$

Jaguar8

Oct 24 07:09

NEWS

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...

Trytosaveabit

Oct 24 07:03

News

$Aquestive Therapeutics (AQST.US)$ Reuters· 1 min ago
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints

Green Dragon 2024

Oct 23 04:31

Increase in shares…

$Aquestive Therapeutics (AQST.US)$